AnaBios
San Diego · 2 known investors
AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials. It offers human tissue procurement and functional assay services, including gene expression, proteomic, and metabolomic profiling, to support drug discovery and preclinical safety testing.
BiotechDeep TechHealthtech
Founders & leadership
AG
Andre GhettiFounder
RF
Richard F. ErdmanNamed on SEC filing
PM
Paul MillerNamed on SEC filing
JR
Jack ReynoldsNamed on SEC filing
PC
Peter CrowleyNamed on SEC filing
GG
George GoldsmithNamed on SEC filing
MJ
Martin J. WatersNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$13.4M disclosed across 3 rounds · 2016–2022
▶$6.5MraisedJun 2022 · 1 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJun 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Melanie FanDirector
- Andre GhettiExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- Richard ErdmanDirector
- Paul E MillerExecutive Officer
- David AndersonDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2020 · 16 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJun 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul E MillerExecutive Officer
- George GoldsmithExecutive Officer
- Richard ErdmanDirector
- Peter CrowleyExecutive Officer, Director
- Jack ReynoldsExecutive Officer, Director
- Andre GhettiExecutive Officer
- Martin WatersExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.1M
- Sales commissions
- $490K
- Placement agents
- ARCADIA SECURITIES, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedJun 2017 · 63 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJun 2017 · 63 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard F. ErdmanDirector
- Paul MillerExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- George GoldsmithDirector
- Martin J. WatersExecutive Officer
- Andre GhettiExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $5.8M
- Finders' fees
- $254.1K
- Placement agents
- CIM Securities, LLC, Brookline Group, LLC
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapOsmosis30 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Lumen26 shared keywordsLumen Learning provides courseware and teaching tools built on open educational resources (OER) for higher education, aimed at faculty and students. Its products support course delivery, faculty professional development, and student-centered learning in colleges and universities.
Companies competing with AnaBios for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $320.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $200.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does AnaBios do?
- AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials. It offers human tissue procurement and functional assay services, including gene expression, proteomic, and metabolomic profiling, to support drug discovery and preclinical safety testing.
- Who founded AnaBios?
- AnaBios was founded by Andre Ghetti.
- Who are AnaBios's investors?
- AnaBios's investors include Ampersand, Keiretsu Forum.
- How much funding has AnaBios raised?
- AnaBios has disclosed $13.4M raised across 3 rounds.
- Where is AnaBios headquartered?
- AnaBios is headquartered in San Diego.